Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo, +14

New England Journal of Medicine

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga, Javier Cortés, Sung‐Bae Kim, +11

New England Journal of Medicine

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, +118

The Lancet Oncology

Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets +8

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo, +224

The Lancet

Chemotherapy Versus PlaceboBreast OncologyOncologyClinical TrialsBreast Cancer +5

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Stephen Chia, Tamas Hickish, V. Harvey, +9

Annals of Oncology

Breast OncologyMedicineBreast CancerPharmacotherapyAnthracycline-free Chemotherapy Regimens +3

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios, +16

The Lancet

Breast OncologyOncologyBreast CancerPharmacotherapyCancer Treatment +4

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim, +216

The Lancet Oncology

End-of-study ResultsBreast OncologyMedicineClinical TrialsPathology +6

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André, +158

Annals of Oncology

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung, +27

The Lancet

Breast OncologyMedicineClinical TrialsPathologyBreast Cancer +6

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, +119

The Lancet Oncology